Royal Bank of Canada
COGT icon

Royal Bank of Canada’s Cogent Biosciences COGT Stock Holding History

Royal Bank of Canada’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36M Buy
60,926
+4,666
+8% +$163K ﹤0.01% 3184
2026
Q1 		$2.17M Buy
56,260
+39,403
+234% +$1.45M ﹤0.01% 3035
2025
Q4 		$599K Sell
16,857
-162,861
-91% -$4.58M ﹤0.01% 4031
2025
Q3 		$2.58M Sell
179,718
-9,990
-5% -$118K ﹤0.01% 3186
2025
Q2 		$1.36M Buy
189,708
+184,383
+3,463% +$1.02M ﹤0.01% 3633
2025
Q1 		$32K Buy
5,325
+867
+19% +$6.8K ﹤0.01% 5741
2024
Q4 		$35K Sell
4,458
-4,801
-52% -$47.8K ﹤0.01% 5859
2024
Q3 		$100K Buy
9,259
+39
+0.4% +$380 ﹤0.01% 5342
2024
Q2 		$78K Buy
9,220
+7,359
+395% +$55.8K ﹤0.01% 5412
2024
Q1 		$13K Sell
1,861
-24,095
-93% -$149K ﹤0.01% 6093
2023
Q4 		$152K Buy
25,956
+14,197
+121% +$109K ﹤0.01% 5316
2023
Q3 		$115K Buy
11,759
+6,129
+109% +$72.7K ﹤0.01% 5291
2023
Q2 		$66K Buy
5,630
+2,027
+56% +$23.3K ﹤0.01% 5629
2023
Q1 		$39K Sell
3,603
-3,642
-50% -$46.6K ﹤0.01% 5749
2022
Q4 		$84K Buy
7,245
+6,182
+582% +$76.6K ﹤0.01% 5584
2022
Q3 		$16K Buy
1,063
+812
+324% +$11.1K ﹤0.01% 6228
2022
Q2 		$2K Sell
251
-2,032
-89% -$13.9K ﹤0.01% 6931
2022
Q1 		$17K Sell
2,283
-4,886
-68% -$34K ﹤0.01% 6681
2021
Q4 		$61K Buy
7,169
+3,342
+87% +$29.1K ﹤0.01% 6245
2021
Q3 		$32K Buy
3,827
+1,283
+50% +$9.83K ﹤0.01% 6420
2021
Q2 		$21K Buy
+2,544
New +$21.5K ﹤0.01% 6536
2021
Q1 		– Sell
-123
Closed -$1K – 7458
2020
Q4 		$1K Buy
+123
New +$1.35K ﹤0.01% 6930
2018
Q4 		– Sell
-42
Closed -$2K – 6794
2018
Q3 		$2K Buy
+42
New +$2.37K ﹤0.01% 6498

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Royal Bank of Canada's COGT Position: Q2 2026 in Review

Royal Bank of Canada increased its Cogent Biosciences (COGT) stake by 8.3% in Q2 2026, buying an estimated $163K and bringing the position to 60,926 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3184.

Royal Bank of Canada first reported a position in COGT in Q3 2018 and has held it in 23 quarters since. The position peaked at $2.58M in Q3 2025. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Royal Bank of Canada held 60,926 shares of Cogent Biosciences worth $2.36M as of Q2 2026.
  • Royal Bank of Canada bought 4,666 Cogent Biosciences shares in Q2 2026, an estimated $163K.
  • Cogent Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #3184 holding.
  • Royal Bank of Canada first reported a position in Cogent Biosciences in Q3 2018 and has held it in 23 quarters since.
  • Royal Bank of Canada's Cogent Biosciences position peaked at $2.58M in Q3 2025.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.